Dr Julia Moore Vogel and Dr Danilo Buonsenso discuss various aspects of long COVID including epidemiology, pathophysiology, underlying mechanisms, management, latest research developments, difficulties in conducting clinical trials, and future research priorities.

Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them.

Series authors discuss their papers on artificial intelligence and infectious diseases intended to support the infectious diseases community in understanding this evolving landscape.

Drs Catherine Liu and Joshua Hill of the Fred Hutchinson Cancer Center discuss their new Series of papers on the prevention and management of infections in people who are immunocompromised, with a focus on prevention of infections and diagnostic and antimicrobial stewardship.

Lilian Tina Minja and Norbert Heinrich discuss the SUDUCO and DECODE trials in The Lancet Infectious Diseases on two new promising TB drugs, sutezolid and delpazolid, respectively. They also discuss the wider implications of the findings of these trials for TB drug development and treatment.

Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond.

Sofia Viegas and Stefan Niemann discuss a new article in The Lancet Infectious Diseases about emerging bedaquiline resistance in Mozambique and its implications for drug resistant tuberculosis and the fight to end tuberculosis.

Jan Felix Drexler and Fernando Bozza discuss their recent study published in the journal— “The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin America” and its wider implications for Oropouche virus and other arboviruses transmission, expansion, surveillance, and control.

Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.

Oriol Mitjà discusses a new trial in The Lancet Infectious Diseases on the use of oral linezolid compared with benzathine penicillin G for the treatment of early syphilis in adults. He also highlights what the trial means for treatment of syphilis.